SEATTLE, April 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today that it will present data regarding its SCORPION(TM) multispecific therapeutic technology at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, April 18-22, 2009.
The company will present data demonstrating the selectivity and high potency of the bispecific CD79BxDR SCORPION molecule and its potential as a therapeutic for B-cell depletion, particularly in diseases refractory to CD20-targeted therapies.
Abstract: 5465 Presentation Title: CD79BxDR SCORPION molecule: a single-chain, bispecific immunotherapeutic with potent in vitro activity against B-cell lymphoma Presentation Time: Wednesday, April 22, 2009, 8 a.m.-noon Location: Hall B-F, Poster Section 33 Presenter: John W. Blankenship, Trubion Pharmaceuticals, Inc.
Trubion's SCORPION(TM) Therapeutics
Like Trubion's SMIP(TM) therapeutics -- single chain polypeptides comprising one binding domain, one hinge domain and one effector domain -- SCORPION therapeutics are also novel, single-chain polypeptides comprised of functional domains from naturally occurring proteins. However, SCORPION therapeutics are multispecific therapeutics that are capable of targeting two or more antigens simultaneously. Trubion's SCORPION format provides the basis for development of single therapies that simultaneously inhibit multiple ligand/receptor interactions or that manipulate cellular signaling pathways by cross-linking multiple cell surface receptors.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary SMIP product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2a clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.
Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's future regulatory filings and the timing and outcome thereof. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the clinical advancement of TRU-016, the company's Wyeth collaboration, including Wyeth's control over development timelines, the risks that the Company is unable to advance its clinical development programs and regulatory applications and action at the rate it expects, and such other risks as identified in the company's annual report on Form 10-K for the period ended December 31, 2008, and from time to time in other reports filed by Trubion with the U.S. Securities and Exchange Commission. These reports are available on the Investors page of the company's corporate Web site at http://www.trubion.com. Trubion undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
Contact: Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. (206) 838-0500 firstname.lastname@example.org http://www.trubion.com Waggener Edstrom Worldwide Healthcare Amy Petty Senior Account Executive (617) 576-5788 email@example.com
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved